ALSO NOTED: Adventrx reports ANX-530 results; FDA to disclose financial ties; and much more...

> Adventrx Pharmaceuticals has announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Release

> The FDA is planning to let some blue sky into its advisory committees. In an attempt to stifle conflicts of interest, the agency wants to tell the public about any advisory committee member's financial ties to the drug industry. Report

> Drug dosages, especially antibiotics, are often incorrect for obese patients. Release

> A Danish study found that patients using the Sanofi-Aventis' Acomplia almost doubled their risk for depression. Report

> It looks as if the big Vioxx settlement offers plaintiffs not just the carrot, but the stick, too. If one of an attorney's clients accepts the deal, then that lawyer has to recommend it to the rest of his or her Vioxx clients. The lawyer then has to fire any clients who hold out. Report

> Takeda is launching new ads touting its star diabetes drug today, saying, "If you have type 2 diabetes, Actos has been shown to lower blood sugar without increasing your risk of having a heart attack or stroke." If you think it sounds like it's aimed at GlaxoSmithKline's Avandia, you're right. Report

> Yesterday on the Senate floor, Senator Charles Grassley (R-IA) said that he wants any would-be pharma whistleblowers to call his office. Report

And Finally... Iceland's DeCODE Genetics has launch deCODEme, a service that lets individuals get a detailed look at their own genome. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.